These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37390233)

  • 1. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs.
    Zhou H; Toshiyoshi M; Zhao W; Zhao Y; Zhao Y
    Medicine (Baltimore); 2023 Jun; 102(26):e33981. PubMed ID: 37390233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
    Zhao Y; Zhao W; Wang H; Zhao Y; Bu H; Takahashi H
    Medicine (Baltimore); 2022 Nov; 101(46):e31508. PubMed ID: 36401449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
    Fatima K; Moeed A; Waqar E; Atif AR; Kamran A; Rizvi H; Suri NF; Haider H; Shuja SH; Khalid M; Minhas AMK
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101816. PubMed ID: 34607067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Huazhi Rougan granule in the treatment of non-alcoholic fatty liver: a systematic review and meta-analysis.
    Wang T; Song J; Hu J; Feng S; Zhang H; Wang H; Li B
    Ann Palliat Med; 2021 Dec; 10(12):12969-12984. PubMed ID: 33691456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins for the Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Dai W; Xu B; Li P; Weng J
    Am J Ther; 2023 Jan-Feb 01; 30(1):e17-e25. PubMed ID: 36608070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis.
    Pastori D; Pani A; Di Rocco A; Menichelli D; Gazzaniga G; Farcomeni A; D'Erasmo L; Angelico F; Del Ben M; Baratta F
    Br J Clin Pharmacol; 2022 Feb; 88(2):441-451. PubMed ID: 34133035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Different Exercise Methods on Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Meta-Regression.
    Xiong Y; Peng Q; Cao C; Xu Z; Zhang B
    Int J Environ Res Public Health; 2021 Mar; 18(6):. PubMed ID: 33801028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis on the efficacy of statins in the treatment of atherosclerosis.
    Jia J; Zhang L; Wang L; Ji C; Xia R; Yang Y
    Ann Palliat Med; 2021 Jun; 10(6):6793-6803. PubMed ID: 34237978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Liu N; Yang J; Ma W; Li C; An L; Zhang X; Zou Q
    J Ethnopharmacol; 2022 Apr; 288():114999. PubMed ID: 35051605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xuefu Zhuyu decoction for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis.
    Liu J; Dong B; Yang L; Huang W; Tang S
    Medicine (Baltimore); 2021 May; 100(19):e25358. PubMed ID: 34106587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional foods and dietary supplements in the management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Wang LL; Zhang PH; Yan HH
    Front Nutr; 2023; 10():1014010. PubMed ID: 36866059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
    PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to nonalcoholic fatty liver disease: A meta-analysis of twenty studies.
    Zhao Y; Zhao W; Ma J; Toshiyoshi M; Zhao Y
    Medicine (Baltimore); 2023 Mar; 102(10):e33110. PubMed ID: 36897668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Nigella sativa in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Tang G; Zhang L; Tao J; Wei Z
    Phytother Res; 2021 Aug; 35(8):4183-4193. PubMed ID: 33728708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs.
    Zhao Y; Zhao W; Bu H; Toshiyoshi M; Zhao Y
    Medicine (Baltimore); 2023 Feb; 102(6):e32892. PubMed ID: 36820578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
    Palmer SC; Navaneethan SD; Craig JC; Perkovic V; Johnson DW; Nigwekar SU; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD005019. PubMed ID: 24470059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Sun L; Deng C; Gu Y; He Y; Yang L; Shi J
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101876. PubMed ID: 35321843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acupoint embedding therapy improves nonalcoholic fatty liver disease with abnormal transaminase: A PRISMA-compliant systematic review and meta-analysis.
    Dai L; Ooi VV; Zhou W; Ji G
    Medicine (Baltimore); 2020 Jan; 99(3):e18775. PubMed ID: 32011470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.